Searle Company Ltd · PSX:SEARL
Searle — The Searle Company — Investor Presentation (November 2024)
18 slides from Searle's investor presentation, November 2024
Slide 1: Corporate Briefing Session 2024
Corporate Briefing Session 2024 The Searle Company Limited Research in the service of mankind
Slide 2: International Brands Private Limited
International Brands Private Limited effective holding Status 1 The Searle Company Limited 50.2% Listed 2 Searle Pakistan Limited 45.4% Public unlisted 3 IBL HealthCare Limited 37.4% Listed 4 Searle Biosciences Private Limited 50.2% Unlisted 5 Nextar Pharma Private Limited 43.8% Unlisted Pharmaceuti
Slide 3: Subsidiaries of The Searle Company Limited
Subsidiaries of The Searle Company Limited Holding Direct subsidiaries Holding Indirect subsidiaries The Searle Company limited 90.6% Searle Pakistan Limited 74.1% IBL HealthCare Limited 100.0% Searle Biosciences Private Limited 87.2% Nextar Pharma Private Limited 100.0% Searle Laboratories Private
Slide 4: Company Information
Company Information Board of directors Audit Committee Human resource & remuneration Mr. Adnan Asdar Ali Chairman Committee Ms. Shaista Khaliq Rehman Chairperson Mr. S. Nadeem Ahmed Chief Executive Officer Mr. Zubair Haider Shaikh Chairman Mr. Zubair Razzak Palwala Director Mr. Adnan Asdar Ali Membe
Slide 5: Our Core Values
Our Core Values Excellence Passion • Takes ownership of current role and • Source of energy in the workplace beyond • Demonstrates entrepreneurial drive • Delivers quality work • Shows grit • Strives for continuous improvement • Collaborates Selflessly • Creates transparency • Behaves Respectfully •
Slide 6: Pharmaceutical Industry Overview
Pharmaceutical Industry Overview The global Pakistan pharmaceutical pharmaceutical market industry size is USD 3.2 billion size is USD 1.48 trillion which is approximately 0.2% of global market • Global pharmaceutical industry is expected to grow with PKR billion Compound Annual Growth Rate (CAGR) o
Slide 7: Industry Rankings
Industry Rankings SEARLE IS RANKED NUMBER 2ND IN TERMS OF VOLUME AND RANKEND 5TH IN TERMS OF VALUE Market Market CAGR CAGR % Share% 2024 – VALUE IMS MAT SEP Share% % 2024 – VOLUME IMS MAT SEP GSK 354,619,271 9.6% 1.02 GETZ 69,944,222,843 7.3% 23.09 SEARLE 232,883,542 6.3% 2.88 SAMI 59,596,431,285 6.
Slide 8: Footprint
Footprint Second largest Six brands crossed PKR No.1 in the following therapeutic categories: pharmaceutical company 1 billion sales per annum 1 of Pakistan in terms of • Cardiovascular units sold • Gynae • Cough Suppressant No.2 in the following therapeutic categories: Eight brands crossed More tha
Slide 9: Corporate Achievements and Recognitions
Corporate Achievements and Recognitions Searle was ranked as the most outstanding company in Healthcare sector of Pakistan as per Asiamoney’s Outstanding Companies Poll, 2018 & 2021. Searle has been part of Forbes Asia’s best under a billion rankings from 2017 to 2019. Searle won Asia’s Best Perform
Slide 10: Product categories & therapeutic areas
Product categories & therapeutic areas Categories Therapeutic areas Pharmaceuticals Searle is leading in terms of derived market, having Biopharmaceuticals presence in 85%+ of all pharmaceutical categories Nutraceuticals Nutrition 1. Allergy / Cough / Cold 9. Neurology / Psychiatry Consumer 2. Analg
Slide 11: Leading brands in their therapeutic category
Leading brands in their therapeutic category Cough Hydryllin Muscle Relaxant Nuberol ORS Peditral Extor, Spiromide, Byscard Cardiovascular Tramal, Rotec Analgesic Gravinate, Lomotil, Selanz Gastrointestinal Anaemia Venofer Eye care Cosopt, Trusopt
Slide 12: Our partners
Our partners L Vifor 2 Pine CHEMO Astrazeneca? aN € Msp —{)— Nestle QO we reckitt HocHDORF a~nten EYN UY eaed 1 DEVA (@) BEXIMCO tly casos WHOLEEARTH. Steere anne Gador "pone asvicr DRIES 7) BER “i ORGANON Brom
Slide 13: Exports
Exports Afghanistan Cambodia Kenya Mauritius Export contributes around 11% towards the total revenue of the company. Searle is the second largest pharmaceutical exporter of Pakistan. Myanmar Sri Lanka Philippines Maldives Currently operating in 12 countries and expanding. Uganda Vietnam Laos Oman
Slide 14: Our production facilities
Our production facilities The production is spread over 7 manufacturing facility, engaged in producing pharmaceutical, biopharmaceutical, nutraceutical, nutrition and consumer products. Out of 6, 4 facilities are located in Karachi while 3 in Lahore. The installed capacity and utilisation is as foll
Slide 15: Drug Pricing Policy
Drug Pricing Policy The MRPs of drugs can be adjusted annually based on the Consumer Price Index (CPI) of the preceding financial year, • Essential drugs allowed an increase up to 7% • However, other than essential drugs have been deregulated since February 2024.
Slide 16: Corporate Social Responsibility
Corporate Social Responsibility Considering the importance of education and believing it to be a right of every citizen, Searle supports The Citizens Foundation to help them achieve the cause, empowering children to become agents of positive change. Continuing with our philosophy of being a socially
Slide 17: Financial performance The Searle Company Limited - Consolidated
Financial performance PKR ‘000 The Searle Company Limited - Consolidated 2019 2020 2021 2022 2023 2024 Revenue 18,062,107 20,474,842 26,219,656 29,909,659 33,969,510 38,742,221 Growth% (CAGR 17%) 13% 28% 14% 14% 14% GP% 48% 47% 46% 44% 39% 39% SG&A % 30% 27% 26% 25% 25% 26% EBITDA% 20% 23% 27% 22% 1
Slide 18: Questions?
Questions?
The Searle Company — Investor Presentation (November 2024) on 6ix